China Resources Boya Bio-pharmaceutical Issues Sharp Profit Warning for 2025
China Resources Boya Bio-pharmaceutical, a key player in biologics and medical aesthetics, has warned of a steep profit decline for 2025, projecting net profit attributable to shareholders at RMB105